Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470373 | 0.89 | MCHR1 (0.49) | FAAH | |
| SCHEMBL12471167 | 0.88 | FAAH (0.48) | METFAAHPDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL12470838 | 0.84 | MAPT (0.54) | METKMT2ALIPELMNASMN1; SMN2 | |
| SCHEMBL15391665 | 0.80 | SMN1; SMN2 (0.60) | KMT2ALIPELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14783578 | 0.78 | MET (0.49) | METFAAHPDE3BPDE3AALDH1A1 | |
| SCHEMBL12471018 | 0.76 | MET (0.43) | METPDE3BPDE3AALDH1A1MAPT | |
| SCHEMBL12470876 | 0.76 | MCHR1 (0.41) | FAAHKMT2AALDH1A1 | |
| SCHEMBL3153818 | 0.74 | NPC1 (0.45) | KMT2ALMNAPDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL21190208 | 0.74 | ALDH1A1 (0.47) | LMNASMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL2699459 | 0.74 | ALDH1A1 (0.55) | METLMNASMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673277-A1 | [1, 2, 4]TRIAZOLO [4, 3 -B]PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | Novartis AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| WO-2012107500-A1 | [1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | MET, ERBB2, RET | MET 1/4885FAAH 4656/4885KMT2A 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.